BioAge Labs Inc. Stock Price, News & Analysis

BioAge (NASDAQ: BIOA) reported Q3 2025 results and program updates on Nov 6, 2025. The company dosed the first participant in the Phase 1 trial of BGE-102, an oral CNS-penetrant NLRP3 inhibitor, with initial single ascending dose (SAD) data expected by year-end 2025. BioAge is advancing oral and parenteral APJ agonist programs targeting 2026 IND submissions and continues collaborations with Novartis and Lilly.

Financial highlights: collaboration revenue was $2.1M; R&D expense was $18.5M; G&A expense was $6.7M; net loss was $20.2M or $0.56 per share; cash and marketable securities were $295.9M, sufficient to fund operations through 2029.

BioArctic (Nasdaq Stockholm: B) will publish its third quarter report for July–September 2025 on Thursday, 13 November 2025 at 08:00 CET. An English-language audiocast with teleconference will follow the report on 13 November 2025 at 09:30 CET, where CEO Gunilla Osswald and CFO Anders Martin-Löf with colleagues will present the report and hold a Q&A.

Investors, analysts and media can join via webcast (written questions) or teleconference (verbal questions) after registration. The webcast will be available on demand on BioArctic's investor website. Contact: Oskar Bosson, VP Communications and Investor Relations.

BioArctic (NASDAQ: B) announced that partner Eisai received a Notice of Compliance with Conditions (NOC/c) from Health Canada for Leqembi (lecanemab) on October 27, 2025, authorizing use in adults with early Alzheimer’s disease who are ApoE ε4 non-carriers or heterozygotes and have confirmed amyloid pathology.

Leqembi is described as the first treatment targeting an underlying cause of early AD and shown in the Phase 3 Clarity AD study to slow cognitive and functional decline; it is approved in 51 countries and regions. The Canadian authorization is conditional pending confirmatory trials and Eisai will submit real-world clinical assessment data. BioArctic retains Nordic commercialization rights and plans joint regional commercialization with Eisai.

BioArctic (Nasdaq Stockholm: BIOA) announced on October 14, 2025 that Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanemab for Alzheimer's disease, was selected by TIME as one of the Best Inventions of 2025 in the Medical and Healthcare category.

The selection recognizes the product's innovation and potential impact. Leqembi was developed in collaboration with Eisai, which leads clinical development, regulatory approvals and global commercialization. BioArctic retains rights to commercialize Leqembi in the Nordic region together with Eisai. Prescribing information in the US includes a Boxed WARNING.

BioArctic (NASDAQ: BIOA) partner Eisai launched Leqembi Iqlik (lecanemab-irmb) subcutaneous autoinjector in the U.S. on October 6, 2025 as a maintenance option for early Alzheimer’s disease (MCI or mild dementia) after an initial 18-month IV induction.

After 18 months of 10 mg/kg IV every two weeks, patients may continue IV every four weeks or switch to a weekly 360 mg at-home subcutaneous injection. The company also launched a Leqembi Companion program with nurse education, financial/insurance support, an injection tracker and an app. Full prescribing information and a boxed warning apply.

BioArctic AB (Nasdaq Stockholm: BIOA B) announced that its partner Eisai has received approval from China's NMPA for Leqembi's (lecanemab) IV maintenance treatment in early Alzheimer's disease. The new approval allows for a maintenance dosing regimen of 10 mg/kg once every four weeks after an 18-month initiation phase of bi-weekly dosing.

Leqembi, initially approved in China in January 2024, is notable as the only approved therapy targeting both amyloid plaque and protofibrils in Alzheimer's disease treatment. The drug was developed through a collaboration between BioArctic and Eisai, based on Professor Lars Lannfelt's research on the Arctic mutation in Alzheimer's disease.

BioArctic AB (Nasdaq Stockholm: BIOA B) announced that Australia's Therapeutic Goods Administration (TGA) has approved Leqembi (lecanemab) for treating early Alzheimer's disease. The approval specifically targets adult patients with mild cognitive impairment or mild dementia who are apolipoprotein E ε4 non-carriers or heterozygotes with confirmed amyloid pathology.

This approval follows a review process initiated in March 2025 after an initial rejection in February 2025. Leqembi, developed through collaboration between BioArctic and Eisai, originated from Professor Lars Lannfelt's research on the Arctic mutation in Alzheimer's disease. While Eisai leads global commercialization, BioArctic maintains Nordic region commercialization rights in partnership with Eisai.

BioAge Labs (NASDAQ:BIOA) has initiated a Phase 1 clinical study of BGE-102, a novel brain-penetrant NLRP3 inhibitor developed in collaboration with HitGen (SSE:688222). The drug candidate, discovered using HitGen's DNA-encoded library (DEL) technology platform, is being developed initially for obesity treatment.

BGE-102 is an orally available small molecule that targets NLRP3, a key driver of age-related inflammation implicated in neurodegenerative conditions, cardiovascular disease, and metabolic disorders. The clinical trial initiation triggers an undisclosed milestone payment to HitGen under their collaboration agreement.

The partnership, which began with successful hit identification in April 2021, has resulted in joint patent filings and a published research paper in February 2024. Both companies continue to collaborate on additional drug discovery programs using HitGen's DEL platform, which contains over 1.2 trillion small molecules.

BioArctic (NASDAQ STOCKHOLM: BIOA B) announced that CEO Gunilla Osswald has been named Uppsala University's Alumnus of the Year 2025. The recognition highlights her exemplary leadership and contributions to scientific innovation, particularly in the development of lecanemab for Alzheimer's disease.

Earlier in March 2025, Osswald and BioArctic's founders were also awarded the university's Innovation and Entrepreneurship Prize. The university praised her visionary and inclusive leadership style, noting her ability to foster collaboration and serve as a role model for women in science and technology.